Agilent Technologies, Inc. A SPX
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 21.3%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | A Agilent Technologies, Inc. SPX | 135.53 | 27.27 | $38.25B | 0.75% | 14.90% | 21.33% | 0.48% | 1.29% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jul 2013 | Jan 2014 | Apr 2014 | Jul 2014 | Jan 2015 | Apr 2015 | Jul 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.11B | 1.21B | 1.21B | 1.20B | 1.28B | 1.24B | 1.27B | 1.36B | 1.24B | 1.26B | 1.55B | 1.52B | 1.59B | 1.67B | 1.61B | 1.72B | 1.76B | 1.72B | 1.67B | 1.66B | 1.57B | 1.58B | 1.68B | 1.67B | 1.74B | 1.86B | 1.80B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 782.00M | 802.00M | 850.00M | 871.00M | 852.00M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 899.00M | 866.00M | 888.00M | 990.00M | 946.00M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 523.00M | 566.00M | 528.00M | 547.00M | 593.00M | - |
| Operating Income | 236.00M | 124.00M | 94.00M | 131.00M | 115.00M | 107.00M | 144.00M | 155.00M | 131.00M | 146.00M | 206.00M | 201.00M | 201.00M | 229.00M | 210.00M | 221.00M | 250.00M | 216.00M | 225.00M | 215.00M | 102.00M | 230.00M | 328.00M | 288.00M | 336.00M | 376.00M | 360.00M | 411.00M | 426.00M | 383.00M | 133.00M | 384.00M | 363.00M | 333.00M | 376.00M | 300.00M | 360.00M | 443.00M | 353.00M | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 467.00M | 362.00M | 466.00M | 540.00M | 456.00M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.00M | 29.00M | 28.00M | 27.00M | 25.00M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 367.00M | 260.00M | 366.00M | 442.00M | 364.00M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.00M | 45.00M | 30.00M | 8.00M | 59.00M | - |
| Net Income | - | - | - | - | - | - | - | 121.00M | 91.00M | 124.00M | 168.00M | 164.00M | 175.00M | -320.00M | 205.00M | 236.00M | 504.00M | 182.00M | 191.00M | 197.00M | 101.00M | 199.00M | 288.00M | 216.00M | 264.00M | 283.00M | 274.00M | 329.00M | 352.00M | 302.00M | 111.00M | 348.00M | 308.00M | 282.00M | 318.00M | 215.00M | 336.00M | 434.00M | 305.00M | - |
| Diluted EPS | 0.49 | 0.58 | 0.41 | 0.43 | 0.19 | 0.26 | 0.33 | 0.36 | 0.28 | 0.38 | 0.52 | 0.50 | 0.54 | -0.99 | 0.63 | 0.73 | 1.57 | 0.57 | 0.60 | 0.63 | 0.32 | 0.64 | 0.93 | 0.70 | 0.86 | 0.93 | 0.91 | 1.10 | 1.19 | 1.02 | 0.38 | 1.18 | 1.05 | 0.97 | - | 0.75 | 1.18 | 1.53 | 1.07 | 1.20 |
| R&D Expense | 171.00M | 88.00M | 87.00M | 86.00M | 88.00M | 81.00M | 79.00M | 78.00M | 81.00M | 86.00M | 79.00M | 84.00M | 87.00M | 94.00M | 92.00M | 97.00M | 102.00M | 99.00M | 101.00M | 104.00M | 197.00M | 92.00M | 103.00M | 109.00M | 113.00M | 117.00M | 115.00M | 116.00M | 123.00M | 126.00M | 118.00M | 128.00M | 113.00M | 127.00M | 113.00M | 112.00M | 111.00M | - | 117.00M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 4.20B | 4.47B | 4.91B | 5.16B | 5.34B | 6.32B | 6.85B | 6.83B | 6.51B | 6.95B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.13B | 3.37B | 2.98B | 3.31B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.72B | 3.46B | 3.54B | 3.64B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.10B | 2.12B | 2.05B | 2.16B |
| Operating Income | 584.00M | 795.00M | 47.00M | 566.00M | 1.07B | 1.12B | 386.00M | 419.00M | 522.00M | 615.00M | 807.00M | 904.00M | 941.00M | 846.00M | 1.35B | 1.62B | 1.35B | 1.49B | 1.48B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.91B | 1.71B | 1.87B | 1.83B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 84.00M | 95.00M | 96.00M | 112.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.50B | 1.34B | 1.52B | 1.44B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 250.00M | 99.00M | 232.00M | 132.00M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 719.00M | 1.21B | 1.25B | 1.24B | 1.29B | 1.30B |
| Diluted EPS | 1.57 | 1.87 | -0.09 | 1.94 | 2.85 | 3.27 | 2.13 | 1.62 | 1.20 | 1.40 | 2.10 | 0.97 | 3.37 | 2.30 | 3.94 | 4.18 | 4.19 | 4.43 | 4.57 |
| R&D Expense | 685.00M | 704.00M | 642.00M | 612.00M | 649.00M | 668.00M | 337.00M | 358.00M | 330.00M | 329.00M | 341.00M | 387.00M | 404.00M | 495.00M | 441.00M | 467.00M | 481.00M | 479.00M | 455.00M |
Compounded Sales Growth
| 5 Years: | 0.48% |
| 1 Year: | 10.00% |
Compounded Profit Growth
| 5 Years: | 1.29% |
| 1 Year: | 60.00% |
Stock Price Performance
| 1 Year: | +22.09% |
| 6 Months: | -13.43% |
| 3 Months: | +11.91% |
| 1 Month: | +21.77% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2006 | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Nov 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.01B | 7.61B | 9.70B | 9.06B | 10.54B | 10.69B | 10.81B | 7.48B | 7.79B | 8.43B | 8.54B | 8.56B | 9.45B | 9.63B | - | 10.53B | 10.76B | 11.85B | 12.73B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.78B | 4.19B | 3.96B | 4.59B |
| Cash & Equivalents | 2.26B | 1.83B | 1.41B | 2.48B | 2.65B | 3.53B | 2.35B | 2.67B | 2.22B | 2.00B | 2.29B | 2.68B | 2.25B | 2.25B | 1.38B | 1.44B | - | 1.05B | 1.59B | 1.33B | 1.79B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04B | 1.03B | 972.00M | 1.02B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.41B | 1.29B | 1.32B | 1.49B |
| Total Liabilities | - | - | 4.45B | 5.10B | 6.46B | 4.74B | 5.35B | 5.40B | 5.51B | 3.31B | 3.55B | 3.59B | 3.97B | 3.96B | 4.70B | 4.75B | - | 5.23B | 4.92B | 5.95B | 5.99B |
| Current Liabilities | - | - | 1.33B | 1.12B | 3.08B | 1.84B | 1.89B | 1.60B | 1.69B | 976.00M | 945.00M | 1.26B | 1.17B | 1.16B | 2.08B | 1.47B | - | 1.86B | 1.60B | 1.90B | 2.35B |
| Long Term Debt | - | - | 1.51B | 2.90B | 2.19B | 1.93B | 2.11B | 2.70B | 1.66B | 1.66B | 1.90B | 1.80B | 1.80B | 1.80B | 1.79B | 2.28B | - | 2.73B | 2.73B | 3.35B | 3.05B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.77B | 2.73B | 3.39B | 3.35B |
| Total Equity | 3.65B | 3.23B | 2.56B | 2.51B | 3.23B | 4.31B | 5.18B | 5.29B | 5.30B | 4.17B | 4.24B | 4.83B | 4.57B | 4.59B | 4.75B | 4.87B | - | 5.30B | 5.84B | 5.90B | 6.74B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 295.00M | 292.12M | 285.19M | 283.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 969.00M | 756.00M | 408.00M | 718.00M | 1.26B | 1.23B | 1.15B | 731.00M | 512.00M | 793.00M | 889.00M | 1.09B | 1.02B | 921.00M | - | 1.31B | 1.77B | 1.75B | 1.56B |
| Investing Cash Flow | -456.00M | -399.00M | -14.00M | -1.17B | 1.29B | -2.37B | -248.00M | -230.00M | -400.00M | -238.00M | -304.00M | -705.00M | -1.59B | -147.00M | - | -338.00M | -310.00M | -1.26B | -394.00M |
| Financing Cash Flow | -980.00M | -774.00M | 657.00M | 601.00M | -1.69B | -37.00M | -554.00M | -117.00M | -1.09B | -268.00M | -202.00M | -797.00M | -299.00M | -717.00M | - | -1.37B | -930.00M | -752.00M | -715.00M |
| Capital Expenditure | -154.00M | -154.00M | -128.00M | -121.00M | -188.00M | -194.00M | -195.00M | -205.00M | -98.00M | -139.00M | -176.00M | -177.00M | -155.00M | -119.00M | - | -291.00M | -298.00M | -378.00M | -407.00M |
| Free Cash Flow | 815.00M | 602.00M | 280.00M | 597.00M | 1.07B | 1.03B | 957.00M | 526.00M | 414.00M | 654.00M | 713.00M | 910.00M | 866.00M | 802.00M | - | 1.02B | 1.47B | 1.37B | 1.15B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -398.00M | 532.00M | -259.00M | 450.00M |
| Share Buybacks | 1.94B | 1.00B | 157.00M | 411.00M | 497.00M | 172.00M | 900.00M | 200.00M | 267.00M | 434.00M | 194.00M | 422.00M | 723.00M | 469.00M | 788.00M | 1.14B | 575.00M | 1.15B | 425.00M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.4% | 50.7% | 54.3% | 52.4% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | 14.6% | 18.0% | 18.4% | 18.2% | 15.8% | 21.3% | 23.6% | 19.8% | 22.9% | 21.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.5% | 19.1% | 18.3% | 18.1% | 19.8% | 18.8% |
| ROE % | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.8% | - | 23.6% | 21.2% | 21.9% | 19.3% |
| ROCE % | - | 14.0% | 0.7% | 8.6% | 14.8% | 12.9% | 4.2% | 4.6% | 8.0% | 9.0% | 11.3% | 12.3% | 12.8% | 10.4% | - | 18.7% | 14.7% | 15.0% | 14.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.17% | 25.90M | $3.51B |
| 2 | Vanguard Capital Management LLC | 6.50% | 18.38M | $2.49B |
| 3 | Vanguard Portfolio Management LLC | 5.08% | 14.35M | $1.95B |
| 4 | State Street Corporation | 4.52% | 12.76M | $1.73B |
| 5 | Massachusetts Financial Services Co. | 4.47% | 12.62M | $1.71B |
| 6 | T. Rowe Price Investment Management, Inc. | 3.18% | 8.99M | $1.22B |
| 7 | Geode Capital Management, LLC | 2.66% | 7.52M | $1.02B |
| 8 | Wellington Management Group, LLP | 2.57% | 7.26M | $983.46M |
| 9 | Deutsche Bank AG | 2.12% | 5.98M | $811.03M |
| 10 | Morgan Stanley | 1.75% | 4.95M | $670.76M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for A
I went looking for the AI weed vape that gives you Bitcoin for smoking
The crypto weed vape found me on 4/20, the high holiday of cannabis enthusiasts everywhere. It arrived over Slack with the thumbnail of a man exhaling a plume of vapor, the words "every hit delivers B…
How one founder’s bet on ‘the old school web’ is paying off
Craig Campbell walked away from the river of investor money flowing into AI to create, of all things, a website. Sure, Campbell probably could have started an AI company. He's a former engineer at Met…
AI grifters are creating fake Black people to sell Shein junk
Aliyah, a light-skinned Black woman dressed in country-western gear, is struggling to sell metal buckles she handmade on TikTok. In a video for the social media platform from March, she cries to the c…
The SpaceX IPO is great for Elon Musk and terrible for you
I haven't seen anything as stupid as the WeWork IPO document in a very long time - that is, until Elon Musk filed to take SpaceX public. WeWork was a joke. SpaceX is a threat. And if Musk and his bank…
Tech companies desperately want to film you doing chores
This week, an AI training startup called Shift said it would clean New Yorkers' homes for free. It has plans to expand into other cities as well, including London, and looking around my flat, I get th…